Details of the Drug
General Information of Drug (ID: DM28XTE)
| Drug Name |
2-Furan-2-yl-3-phenethyl-3H-quinazolin-4-one
|
||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Synonyms |
CHEMBL180336; 2-(furan-2-yl)-3-phenethylquinazolin-4-one; AC1LEB94; 2-Furan-2-yl-3-phenethyl-3H-quinazolin-4-one; Oprea1_070906; 2-(2-furyl)-3-(2-phenylethyl)-4(3H)-quinazolinone; ZINC49416; NPS-53574; BDBM50162542; STK674065; AKOS005593239; MCULE-4160039246; ST008066; J3.621.250K; 2-(2-furyl)-3-phenethyl-4(3H)-quinazolinone; AG-205/11559428; SR-01000416527; SR-01000416527-1; 2-(2-furyl)-3-(2-phenylethyl)-3-hydroquinazolin-4-one; 2-(furan-2-yl)-3-(2-phenylethyl)quinazolin-4(3H)-one; A1715/0073151
|
||||||||||||||||||
| Indication |
|
||||||||||||||||||
| Drug Type |
Small molecular drug
|
||||||||||||||||||
| Structure |
![]() |
||||||||||||||||||
| 3D MOL | 2D MOL | ||||||||||||||||||
| #Ro5 Violations (Lipinski): 0 | Molecular Weight (mw) | 316.4 | |||||||||||||||||
| Logarithm of the Partition Coefficient (xlogp) | 3.9 | ||||||||||||||||||
| Rotatable Bond Count (rotbonds) | 4 | ||||||||||||||||||
| Hydrogen Bond Donor Count (hbonddonor) | 0 | ||||||||||||||||||
| Hydrogen Bond Acceptor Count (hbondacc) | 3 | ||||||||||||||||||
| Chemical Identifiers |
|
||||||||||||||||||
| Cross-matching ID | |||||||||||||||||||
| Drug-Molecule Activity Atlas (DMA)NEW | Click to Jump to the Detailed DMA Information of This Drug | ||||||||||||||||||
Molecular Interaction Atlas of This Drug
![]() Drug Therapeutic Target (DTT) |
|
||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Molecular Interaction Atlas (MIA) | |||||||||||||||||||||
Molecular Expression Atlas of This Drug
| The Studied Disease | Discovery agent | |||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ICD Disease Classification | N.A. | |||||||||||||||||
|
||||||||||||||||||
| Molecular Expression Atlas (MEA) | ||||||||||||||||||


